A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration—the FALCON study
Authors
Holz FG, Schmitz-Valckenberg S, Wolf A, Clemens A, et al., Jaeger K
Journal
Graefe’s Archive for Clinical and Experimental Ophthalmology
A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration—the FALCON study - Publication by Dr. Andreas Clemens | Dr. Andreas Clemens